HU9403512D0 - Purified forms of dnase - Google Patents

Purified forms of dnase

Info

Publication number
HU9403512D0
HU9403512D0 HU9403512A HU9403512A HU9403512D0 HU 9403512 D0 HU9403512 D0 HU 9403512D0 HU 9403512 A HU9403512 A HU 9403512A HU 9403512 A HU9403512 A HU 9403512A HU 9403512 D0 HU9403512 D0 HU 9403512D0
Authority
HU
Hungary
Prior art keywords
dnase
components
deamidated
purified forms
species
Prior art date
Application number
HU9403512A
Other languages
Hungarian (hu)
Other versions
HUT70468A (en
HU219549B (en
Inventor
John Frenz
Steven J Shire
Mary B Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HU9403512D0 publication Critical patent/HU9403512D0/en
Publication of HUT70468A publication Critical patent/HUT70468A/en
Publication of HU219549B publication Critical patent/HU219549B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.
HU9403512A 1992-06-08 1993-05-28 Purified forms of dnase HU219549B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/895,300 US5279823A (en) 1992-06-08 1992-06-08 Purified forms of DNASE
PCT/US1993/005136 WO1993025670A1 (en) 1992-06-08 1993-05-28 Purified forms of dnase

Publications (3)

Publication Number Publication Date
HU9403512D0 true HU9403512D0 (en) 1995-02-28
HUT70468A HUT70468A (en) 1995-10-30
HU219549B HU219549B (en) 2001-05-28

Family

ID=25404292

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9403512A HU219549B (en) 1992-06-08 1993-05-28 Purified forms of dnase

Country Status (30)

Country Link
US (4) US5279823A (en)
EP (2) EP0644932B1 (en)
JP (1) JP3383307B2 (en)
KR (2) KR100302092B1 (en)
AT (2) ATE455557T1 (en)
AU (1) AU682822B2 (en)
BG (1) BG62335B1 (en)
BR (1) BR9306670A (en)
CA (1) CA2137237C (en)
CZ (1) CZ293105B6 (en)
DE (3) DE69329200T2 (en)
DK (1) DK0644932T3 (en)
ES (1) ES2150447T3 (en)
FI (1) FI945549A (en)
GB (1) GB2282140B (en)
GE (1) GEP20002300B (en)
GR (1) GR3034718T3 (en)
HU (1) HU219549B (en)
IL (1) IL105724A (en)
MD (1) MD960288A (en)
NO (1) NO318644B1 (en)
NZ (1) NZ253559A (en)
PL (1) PL175873B1 (en)
PT (1) PT644932E (en)
RO (1) RO117188B1 (en)
RU (1) RU2238320C2 (en)
SK (1) SK282957B6 (en)
TJ (1) TJ396B (en)
UA (1) UA46693C2 (en)
WO (1) WO1993025670A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE176924T1 (en) * 1988-12-23 1999-03-15 Genentech Inc METHOD FOR PRODUCING HUMAN DNASE
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
WO1995023854A1 (en) * 1994-03-04 1995-09-08 Genentech, Inc. IMPROVED DNase LIQUID SOLUTIONS
ATE268605T1 (en) * 1994-03-04 2004-06-15 Genentech Inc PHARMACEUTICAL ACCEPTABLE DNASE COMPOSITION
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
WO1995030428A1 (en) * 1994-05-05 1995-11-16 Human Genome Sciences, Inc. Human dnase
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
EP0754751B1 (en) * 1994-09-06 2001-09-19 Seiichi Tanuma Novel deoxyribonuclease
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
SK284191B6 (en) 1995-02-24 2004-10-05 Genentech, Inc. Human DNASE I variants
EP0879289B1 (en) * 1996-02-05 2006-07-05 Genentech, Inc. Human dnase resistant to actin inhibition
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
CN1305896C (en) * 1998-05-06 2007-03-21 基因技术股份有限公司 Protein purification by ion exchange chromatography
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
NZ521051A (en) * 2000-02-11 2003-07-25 Profile Respiratory Systems Lt Drug delivery apparatus
DK1285080T3 (en) 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Process for Purification of Alphavirus Replicon Particles
MD20010375A (en) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Mixer
MD2260C2 (en) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Mixer
AU2003265994B2 (en) 2002-09-11 2010-04-01 Genentech, Inc. Protein purification
US7067298B2 (en) 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US20080160577A1 (en) * 2005-02-04 2008-07-03 Glaxo Group Limited Optimization of Heterologous Polypeptide Expression
KR100655438B1 (en) * 2005-08-25 2006-12-08 삼성전자주식회사 Magnetic memory device and method of forming the same
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
BRPI0717439A2 (en) 2006-10-18 2013-11-19 Periness Ltd PHARMACEUTICAL COMPOSITION, AND METHODS FOR TREATING MALE SUBFERTILITY, FOR DETERMINING A FERTLITY STATUS IN A MALE SEX, FOR ASSISTED REPRODUCTION TECHNIQUE FOR A SPECULAR SPULLET REPRODUCTION FOR CULLED SPLIT USE IN AN AUXILIARY REPRODUCTION TECHNIQUE.
KR20150008503A (en) * 2007-10-30 2015-01-22 제넨테크, 인크. Antibody purification by cation exchange chromatography
WO2009123950A2 (en) * 2008-03-31 2009-10-08 The Trustees Of The University Of Pennsylvania Chimera comprising bacterial cytotoxin and methods of using the same
GB2474225A (en) * 2009-07-21 2011-04-13 Biotec Pharmacon Asa DNase for decontamination of reverse transcription and amplification reactions
EP2699680B1 (en) 2011-04-21 2017-12-27 University of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
CN103920144B (en) * 2013-01-15 2016-09-14 吴庄民 The new opplication of the deoxyribonuclease I of recombined human
SG11201610431WA (en) * 2014-06-25 2017-01-27 Jhl Biotech Inc Methods and reagents for purification of proteins
WO2016067944A1 (en) 2014-10-31 2016-05-06 Ｊｃｒファーマ株式会社 Method for producing remcombinant human dnasei
WO2017019876A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
WO2017139643A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
KR102618948B1 (en) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. Residual tumor infiltrating lymphocytes and methods of making and using the same
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
US20230226138A1 (en) 2020-06-01 2023-07-20 Black Cat Bio Limited Compositions and methods for treating infections and netopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Boen T. Khouw Isolation and purification of deoxyribonuclease
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
ATE176924T1 (en) * 1988-12-23 1999-03-15 Genentech Inc METHOD FOR PRODUCING HUMAN DNASE
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Also Published As

Publication number Publication date
WO1993025670A1 (en) 1993-12-23
NO944752L (en) 1994-12-08
DE69329200T2 (en) 2001-04-26
RO117188B1 (en) 2001-11-30
SK149594A3 (en) 1996-01-10
CA2137237A1 (en) 1993-12-23
EP0644932B1 (en) 2000-08-09
EP0644932A1 (en) 1995-03-29
EP1013284A3 (en) 2000-08-30
DE4392749T1 (en) 1995-07-20
NZ253559A (en) 1996-11-26
TJ396B (en) 2004-12-29
GB2282140A (en) 1995-03-29
US5279823A (en) 1994-01-18
CZ293105B6 (en) 2004-02-18
IL105724A0 (en) 1993-09-22
US6932965B2 (en) 2005-08-23
IL105724A (en) 1997-06-10
NO318644B1 (en) 2005-04-25
FI945549A0 (en) 1994-11-25
GR3034718T3 (en) 2001-01-31
AU4398193A (en) 1994-01-04
BG62335B1 (en) 1999-08-31
FI945549A (en) 1994-11-25
GB2282140B (en) 1996-04-17
US5783433A (en) 1998-07-21
AU682822B2 (en) 1997-10-23
US6440412B1 (en) 2002-08-27
EP1013284B1 (en) 2010-01-20
RU2238320C2 (en) 2004-10-20
ATE195340T1 (en) 2000-08-15
RU94046424A (en) 1997-03-10
JP3383307B2 (en) 2003-03-04
BG99234A (en) 1995-07-28
NO944752D0 (en) 1994-12-08
KR100323357B1 (en) 2002-02-19
PL175873B1 (en) 1999-02-26
CZ303294A3 (en) 1995-06-14
US20030077267A1 (en) 2003-04-24
PT644932E (en) 2001-02-28
DE69334317D1 (en) 2010-03-11
SK282957B6 (en) 2003-01-09
DK0644932T3 (en) 2001-01-02
GB9423695D0 (en) 1995-01-11
UA46693C2 (en) 2002-06-17
DE69329200D1 (en) 2000-09-14
ATE455557T1 (en) 2010-02-15
HUT70468A (en) 1995-10-30
HU219549B (en) 2001-05-28
MD960288A (en) 1998-01-31
GEP20002300B (en) 2000-11-25
EP1013284A2 (en) 2000-06-28
KR100302092B1 (en) 2001-10-22
ES2150447T3 (en) 2000-12-01
BR9306670A (en) 1998-12-08
CA2137237C (en) 2004-10-26
JPH07507455A (en) 1995-08-24

Similar Documents

Publication Publication Date Title
GB2282140B (en) Purified forms of dnase
FI862011A (en) THERAPEUTIC NUCLEOSIDER.
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
GR3006815T3 (en)
ZA895345B (en) Therapeutic compounds
ATE181239T1 (en) USE OF SPRAY EXTRACT FOR THE PRODUCTION OF PREPARATIONS FOR ORAL ADMINISTRATION
MY102687A (en) Novel galenical comprising a somatostatin formulations.
ATE84543T1 (en) PRODUCTION OF HIGHLY PURIFIED HUMAN FACTOR IX AND OTHER PLASMAPROTEIN CONCENTRATE AND THERAPEUTIC USE THEREOF.